BioSpace News Archive

Bristol Myers Squibb announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma.

Sutro Biopharma, Inc. announced that on February 15, 2023, the Compensation Committee of Sutro’s Board of Directors granted 90,000 shares of Sutro Biopharma stock options and 130,000 restricted stock units of Sutro common stock.

Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval to FILSPARI™ to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g.

TransCode Therapeutics, Inc. announced the closing of its previously announced registered direct offering of 2,846,300 shares of common stock priced at-the-market under Nasdaq rules at $0.527 per share for gross proceeds of $1.5 million.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the U.S. Food and Drug Administration has approved SYFOVRE™ for the treatment of geographic atrophy secondary to age-related macular degeneration.

LumiraDx Limited announced that it has received confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450.

Stryker, one of the world’s leading medical technology companies, announced that its Q Guidance System with Cranial Guidance Software received 510 clearance from the U.S. Food and Drug Administration.

An international panel led by a pediatric neuroimmune expert and co-director of the Neuroscience Center at Children’s Hospital of Philadelphia has established new criteria for properly diagnosing myelin oligodendrocyte glycoprotein antibody-associated diseased, a neurological disorder that causes inflammation and potential damage of the brain, spinal cord and optic nerves.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Sorrento Therapeutics, Inc. posted an update to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento.